Trial Profile
A placebo controlled phase III double blind study of ITK-1 -The efficacy and safety evaluation of ITK-1 in Temozolomide refractory Glioblastoma patients with HLA-A24 positive-
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs ITK 1 (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- 30 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 Primary endpoint (Overall survival) has not been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology